8-KOther Events

ELI LILLY & Co 8-K Report (Apr 22, 2003)

Filed April 22, 2003For Securities:LLY

Summary

Eli Lilly & Company (LLY) filed an 8-K on April 22, 2003, to report its financial results for the quarter ended March 31, 2003. The report highlights the company's use of non-GAAP financial measures, specifically adjusted net income and diluted earnings per share, which exclude certain charges like restructurings and asset impairments. Management believes these adjusted figures offer investors a clearer view of underlying operational performance and trends, by removing highly variable and potentially distorting items. While these non-GAAP measures are presented as valuable for understanding period-over-period performance and identifying operational trends, the company emphasizes that they should be considered alongside, not as a substitute for, GAAP-based financial measures. The report also notes that Lilly's earnings guidance may be subject to adjustments for these excluded items, as their prospective quantification is often not feasible. Investors should refer to the press release and related financial statements, attached as Exhibit 99, for detailed financial information and further discussion.

Key Highlights

  • 1Eli Lilly & Company (LLY) announced its first-quarter 2003 financial results via an 8-K filing on April 22, 2003.
  • 2The company is utilizing non-GAAP financial measures, including adjusted net income and diluted earnings per share.
  • 3These non-GAAP measures exclude the impact of restructurings, asset impairments, and other special charges.
  • 4Lilly's management believes these adjusted metrics provide a better understanding of ongoing operational performance.
  • 5The use of non-GAAP measures aims to help investors evaluate period-over-period operational trends.
  • 6Investors are cautioned to consider non-GAAP measures in conjunction with, not as a replacement for, GAAP financial statements.
  • 7Earnings guidance provided by the company may be adjusted for the excluded special charges.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report Eli Lilly & Company's financial results for the quarter ended March 31, 2003, and to disclose the company's use of non-GAAP financial measures.

Eli Lilly is using adjusted (or 'normalized') net income and diluted earnings per share as non-GAAP financial measures. These metrics exclude the impact of specific items such as restructurings, asset impairments, and other special charges.

The company believes these non-GAAP measures provide useful information to investors by helping them evaluate underlying operational performance and identify operating trends that might otherwise be obscured by the excluded, often variable and unpredictable, special charges.

Investors should consider these non-GAAP measures in addition to, and not as a substitute for, or superior to, financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). The company also notes that its earnings guidance may be adjusted for these excluded items.